Megamox Duo (Amoxicillin Trihydrate, Potassium Clavulanate)

Megamox Duo, a combination beta‑lactam antibiotic, is used to treat bacterial infections affecting various organ systems.

• Acute bacterial sinusitis: reduces sinus inflammation and promotes resolution of infection.
• Community‑acquired pneumonia: eradicates the causative bacteria and improves respiratory function.
• Acute otitis media: clears middle‑ear infection and alleviates pain and fever.
• Skin and soft‑tissue infections: eliminates pathogenic bacteria, supporting wound healing and symptom relief.
• Uncomplicated urinary tract infection: eradicates uropathogens, relieving dysuria and preventing recurrence.
• Acute bacterial exacerbation of chronic bronchitis: reduces bacterial load, improves cough and sputum production.

• Amoxicillin trihydrate binds to penicillin‑binding proteins on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis, which leads to cell lysis. Potassium clavulanate, a β‑lactamase inhibitor, covalently binds to β‑lactamase enzymes produced by resistant bacteria, protecting amoxicillin from enzymatic degradation and extending its antibacterial spectrum. The combined effect results in broad‑spectrum activity against both Gram‑positive and Gram‑negative organisms, including many β‑lactamase‑producing strains.

Megamox Duo may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Diarrhea: loose, watery stools that may be mild to moderate and can occur during treatment.
• Nausea: feeling of sickness often accompanied by stomach discomfort or queasiness.
• Rash: mild skin redness or itching that typically resolves after discontinuation.
• Taste disturbance: altered or metallic taste in the mouth that may affect appetite.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with breathing difficulty, swelling, hives and possible shock, requiring immediate medical attention.
• Clostridioides difficile‑associated colitis: severe, persistent diarrhea due to overgrowth of C. difficile, potentially leading to colitis.
• Liver enzyme elevation: increased transaminases indicating hepatic stress, which may require monitoring of liver function.

Before prescribing Megamox Duo, healthcare professionals should consider several precautionary measures to ensure safe use.

• Allergy assessment: verify patient has no known hypersensitivity to penicillins or β‑lactamase inhibitors.
• Renal function: adjust dose in patients with impaired kidney function or on dialysis.
• Hepatic function: monitor liver enzymes in patients with existing liver disease.
• Concomitant medications: review use of drugs that may interact or increase toxicity.
• Use in pregnancy and lactation: evaluate risk‑benefit ratio as safety data are limited.
• Store at room temperature: keep below 25 °C in the original packaging, protect from moisture.

Megamox Duo can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Probenecid: decreases renal excretion of amoxicillin, raising plasma concentrations and risk of toxicity.
• Warfarin: may enhance anticoagulant effect, increasing bleeding risk.
• Methotrexate: can raise methotrexate levels, leading to heightened toxicity.

Moderate Interactions (Monitor Closely)

• Allopurinol: may increase incidence of rash when combined.
• Oral contraceptives: may reduce hormonal efficacy, requiring additional contraceptive measures.